---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-25-000055"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T03:00:05.216387+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inhaled KB707 monotherapy achieves 27% ORR in advanced NSCLC; updated to 36%

## Summary
- 27% ORR (3/11 PR) in heavily pre-treated NSCLC; extended follow-up yields 36% (4/11 PR).
- Median DOR and PFS not reached; responses durable.
- Safety well-tolerated: most TRAEs Grade 1/2, no Grade 4/5; MTD not reached.
- Combination cohort with pembrolizumab enrolling for NSCLC.

## SEC filing metadata
- accession: 0001711279-25-000055
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000055/0001711279-25-000055-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127925000055/krys-20250602.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-25-000055
- JSON: https://secwatch.observer/filing/0001711279-25-000055.json
- Plain text: https://secwatch.observer/filing/0001711279-25-000055.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.